HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Energizer

This article was originally published in The Rose Sheet

Executive Summary

First quarter razors and blades division profit jumped $7.6 mil. to $46.6 mil. on "lower advertising and promotional spending compared to last year's higher spending related to the launch of Quattro in several European markets, as well as lower selling and administrative expenses," firm reports Jan. 23. However, razor and blade sales dropped 5% to $216.1 mil. including impact from currency. Excluding currency, Quattro sales were up 30% over the same quarter last year "on incremental sales from Quattro for Women and Quattro Power," Energizer notes, adding older products offset Quattro gains. Company held a 20.7% overall share in the wet shave category in primary markets for the year ending November 2005, versus 21.5% in the prior year. Net earnings in Q1 were flat at $120.5 mil. and net sales were up $6.5 mil. to $882.4 mil...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013670

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel